Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach

We aimed to develop nafamostat mesylate immediate-release tablets for the treatment of COVID-19 through drug repositioning studies of nafamostat mesylate injection. Nafamostat mesylate is a serine protease inhibitor known to inhibit the activity of the transmembrane protease, serine 2 enzyme that af...

Full description

Bibliographic Details

Published in:	Pharmaceutics
Main Authors:	Hyeon-A Kim, Joo-Eun Kim
Format:	Article
Language:	English
Published:	MDPI AG 2022-06-01
Subjects:	nafamostat mesylate immediate-release tablets COVID-19 quality-by-design approach drug repositioning pharmacokinetic study
Online Access:	https://www.mdpi.com/1999-4923/14/6/1219